Antibodies Against Lysophosphatidic Acid Protect Against Blast-Induced Ocular Injuries

Area of Science:

• Ophthalmology
• Neuroscience
• Immunology

Background:

• Blast overpressure waves cause ocular injuries and visual dysfunction in veterans.
• No current therapies effectively treat blast-induced ocular dysfunction.
• Lysophosphatidic acid (LPA) is implicated in inflammatory processes and increases after traumatic brain injury.

Purpose of the Study:

• To evaluate the protective efficacy of a monoclonal LPA antibody against blast-induced ocular injuries.
• To assess the impact of anti-LPA antibody treatment on retinal integrity and visual function post-blast.

Main Methods:

• Administered a single intravenous dose of anti-LPA antibody (25 mg/kg) 1 hour post-blast exposure.
• Exposed mice to a 19 psi blast and analyzed LPA levels in blood plasma.
• Assessed retinal glial cell activation, neuronal morphology, and visual acuity (optokinetic measurements).

Main Results:

• Blast exposure significantly increased LPA levels in blood plasma.
• Anti-LPA antibody treatment reduced glial cell activation and preserved neuronal morphology in the retina.
• Treatment significantly improved visual acuity and enhanced photoreceptor and bipolar cell signaling.

Conclusions:

• Blast exposure triggers LPA release, contributing to ocular injuries.
• Early administration of anti-LPA antibodies offers significant protection against blast-induced visual dysfunction.
• Targeting LPA represents a potential therapeutic strategy for combat-related eye injuries.